Nachrichten zur Aldeyra Therapeutics Inc. Aktie

Aldeyra Therapeutics Aktie: Fortschritte in klinischen Studien

Die Aldeyra Therapeutics Aktie zeigt sich in jüngster Zeit stabil mit leichten Schwankungen. Am 25. Oktober 2024 notierte die Aktie…

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a…

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN,…

Heres Why You Should Invest in Aldeyra (ALDX) Stock Now

Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent…

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a…

Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?

Lyra Therapeutics, Inc. (LYRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in…

ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Lyra Therapeutics, Inc. (NASDAQ: LYRA) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Lyra Therapeutics, Inc.…

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Lyra Therapeutics, Inc.; Urges Lyra Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

Abbott Cooper PLLC Announces Investigation into Lyra Therapeutics, Inc.; Urges Lyra Stockholders to Contact Abbott Cooper…

Aldeyra Therapeutics 10% owner disposes stake worth $4.45M

…

Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More

Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.…

: Aldeyra Therapeutics stock plunges on heavy volume after FDA finds ‘substantive’ issues with NDA for dry-eye disease treatment

Shares of Aldeyra Therapeutics Inc. ALDX plummeted 61.9% toward a 3 1/2-year low in very active morning trading Monday, enough…

Aldeyra Therapeutics, Omeros among healthcare movers

…

Lifshitz Law PLLC Announces Investigations of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), Verizon Communications, Inc. (NYSE: VZ), Eos Energy Enterprises, Inc. (NASDAQ: EOSE), and Hayward Holdings, Inc. (NYSE: HAYW)

NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)…

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)

LOS ANGELES, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action against Aldeyra Therapeutics, Inc.  of Class Action Lawsuit and Upcoming Deadline – ALDX

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

ALDX DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action – ALDX

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Aldeyra, RTX, and Eos and Encourages Investors to Contact the Firm

NEW YORK, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)

LOS ANGELES, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the…

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc. (ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Aldeyra Therapeutics, Inc.…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 – (NASDAQ: ALDX)

NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem

MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 – (NASDAQ: ALDX)

NEW YORK, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lordstown, Aldeyra, and RTX and Encourages Investors to Contact the Firm

NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of a Class Action against Aldeyra Therapeutics, Inc.  and Certain Officers – ALDX

NEW YORK, Sept. 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

ROSEN, LEADING INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALDX

NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

Aldeyra Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; September 29, 2023 deadline

Investors can contact the law firm at no cost to learn more about recovering their losses…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 – (NASDAQ: ALDX)

NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

Aldeyra reports positive mid-stage results for retinitis pigmentosa candidate

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Aldeyra Therapeutics, For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Aldeyra Therapeutics, For: Jun 29

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Aldeyra gains on positive mid-stage data for cough therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Aldeyra Therapeutics, For: Jun 27

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Aldeyra Therapeutics to join Russell 2000 and Russell 3000 indexes

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Aldeyra Therapeutics, For: Jun 21

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Aldeyra Therapeutics Stock Down 24% After FDA Rejects Eye Cancer Treatment

Aldeyra Therapeutics Stock Down 24% After FDA Rejects Eye Cancer Treatment...…

Aldeyra crashes 21% as FDA rejects eye cancer therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

XFRA : 137: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

Aldeyra Therapeutics Says FDA Cites Lack of Evidence For PVRL Drug

Aldeyra Therapeutics Says FDA Cites Lack of Evidence For PVRL Drug...…

XFRA : 137: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

XFRA : INSTRUMENT_SUSPENSION - US01438T1060

Instrument ID [8902382] (137 - US01438T1060) suspended...…

Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study

Aldeyra (ALDX) soars on meeting primary and secondary endpoints in the late-stage study of reproxalap for patients with allergic conjunctivitis....…

Aldeyra Therapeutics Shares Rise 11% After Positive Data for Reproxalap

Aldeyra Therapeutics Shares Rise 11% After Positive Data for Reproxalap...…

Aldeyra, Bioventus top healthcare gainers; Mersana, Bone Biologics among losers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Aldeyra up 7% on late-stage data for conjunctivitis candidate

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-Aldeyra Therapeutics eye treatment meets late-stage study main goal

..., 3) June 15 (Reuters) - Aldeyra Therapeutics said on Thursday its......…

Aldeyra Therapeutics’ stock jumps 11% premarket after announcing positive trial of treatment for allergic conjunctivitis

Aldeyra Therapeutics Inc.’s stock ALDX jumped 11% premarket Thursday, after the biotech announced positive results from a late-stage trial of…

Aldeyra Therapeutics eye treatment meets late-stage study main goal

...(Reuters) - Aldeyra Therapeutics said on Thursday its......…

Form 8-K Aldeyra Therapeutics, For: Jun 15

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Aldeyra Therapeutics GAAP EPS of -$0.27 beats by $0.02

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…